Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Accumulated Expenses: 2017-2022

Historic Accumulated Expenses for Arcus Biosciences (RCUS) over the last 6 years, with Dec 2022 value amounting to $25.0 million.

  • Arcus Biosciences' Accumulated Expenses rose 3.89% to $15.0 million in Q2 2023 from the same period last year, while for Jun 2023 it was $15.0 million, marking a year-over-year increase of 3.89%. This contributed to the annual value of $25.0 million for FY2022, which is 47.06% up from last year.
  • As of FY2022, Arcus Biosciences' Accumulated Expenses stood at $25.0 million, which was up 47.06% from $17.0 million recorded in FY2021.
  • In the past 5 years, Arcus Biosciences' Accumulated Expenses registered a high of $25.0 million during FY2022, and its lowest value of $5.0 million during FY2019.
  • Over the past 3 years, Arcus Biosciences' median Accumulated Expenses value was $17.0 million (recorded in 2021), while the average stood at $17.2 million.
  • Per our database at Business Quant, Arcus Biosciences' Accumulated Expenses fell by 17.82% in 2019 and then spiked by 92.79% in 2020.
  • Arcus Biosciences' Accumulated Expenses (Yearly) stood at $6.0 million in 2018, then declined by 17.82% to $5.0 million in 2019, then surged by 92.79% to $9.5 million in 2020, then soared by 78.14% to $17.0 million in 2021, then soared by 47.06% to $25.0 million in 2022.